• Boston Scientific’s third-quarter 2026 GAAP net income attributable to common stockholders fell 23% year over year to $582 million.
• Net sales rose to $5.14 billion from a year earlier.
• A strategic collaboration with Heartflow will advance AI-powered, CT-guided planning for percutaneous coronary intervention procedures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610280630PR_NEWS_USPR_____NE82628) on October 28, 2026, and is solely responsible for the information contained therein.